Overview

• Bioventus Q3 revenue of $138.7 mln beats analyst expectations, driven by organic growth

• Adjusted EPS for Q3 increases 200% yr/yr, exceeding analyst estimates

• Company reaffirms 2025 revenue, Adjusted EBITDA, and Non-GAAP EPS guidance

Outlook

• Bioventus reaffirms 2025 net sales guidance of $560 mln to $570 mln

• Company expects 2025 Adjusted EBITDA of $112 mln to $116 mln

• Bioventus projects 2025 Non-GAAP EPS of $0.64 to $0.68

Result Drivers

• ORGANIC GROWTH - Q3 organic revenue increased 8% driven by above-market growth across all three areas of the company's portfolio

• DIVESTITURE IMPACT - Reported revenue declined 0.2% due to the prior-year divestiture of the Advanced Rehabilitation Business

• PROFITABILITY IMPROVEMENT - Non-GAAP EPS increased 200% driven by improved operating profitability and lower interest expense

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Bioventus Inc is $15.00, about 56.3% above its November 3 closing price of $6.56

• The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nGNX2ZFq8t

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)